DGNOF (Diagnos) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


DGNOF Diagnos Inc DGNOF
16 GF Score
Price $0.18
GF Value $0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Diagnos Tariff Resilience Score?

Diagnos DGNOF -5.55% 16 Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Diagnos ranks better than 83.48% on this metric.

Diagnos has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Diagnos has Diagnos Inc, involved in AI for healthcare, faces limited direct tariff exposure. However, tariffs on tech imports could affect costs. Its digital focus and potential for alternative suppliers offer some protection.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Diagnos might have Average Resilient.

Diagnos  (OTCPK:DGNOF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Diagnos Tariff Resilience Score Related Terms

DGNOF vs VEEV, BTSG, TEM: Tariff Resilience Score Comparison

For the Health Information Services subindustry, Diagnos's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnos Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Diagnos's Tariff Resilience Score falls into.


DGNOF
16GF Score
Diagnos Inc DGNOF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Diagnos (DGNOF) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Diagnos ranks #111 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 16.5%.
Is Diagnos' Tariff Resilience Score too high?
Diagnos' current Tariff Resilience Score is 6. Based on the distribution chart, Diagnos ranks #111 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Tariff Resilience Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #111 out of 672 companies for Tariff Resilience Score. This places Diagnos in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Diagnos's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 262.2% above its estimated fair value. The current Tariff Resilience Score is 6. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Diagnos (DGNOF), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnos (DGNOF) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnos stock appears to be overvalued. The current stock price of $0.18 is trading 262.2% above its estimated GF Value™ of $0.05. GuruFocus considers Diagnos to be Significantly Overvalued.

Key valuation signals for DGNOF:

  • Tariff Resilience Score: 6
  • GF Value™: $0.05 vs. price of $0.18 (262.2% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score

Get the complete analysis for DGNOF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.05
GF Value